<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271635</url>
  </required_header>
  <id_info>
    <org_study_id>04/320</org_study_id>
    <nct_id>NCT00271635</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid Treatment in CMT1A Trial (AATIC)</brief_title>
  <acronym>AATIC</acronym>
  <official_title>Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Charcot-Marie-Tooth type IA (CMT1A) is the most prevalent hereditary peripheral neuropathy.&#xD;
      Demyelination of peripheral nerves is the hallmark of CMT1A. Ascorbic acid has been shown to&#xD;
      have a favorable influence on myelination in in vitro studies and in a mouse model for CMT1A.&#xD;
      We will study the efficacy and safety of ascorbic acid treatment in young patients with&#xD;
      CMT1A.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Charcot-Marie-Tooth type 1A (CMT1A), or hereditary motor and sensory neuropathy type Ia (HMSN&#xD;
      Ia), is an autosomal dominant disease, most often caused by a 1.5 Mb duplication of&#xD;
      chromosome 17, giving rise to three copies of the peripheral myelin protein 22 gene (PMP22).&#xD;
      Mutations in this gene rarely cause CMT1A. It is a primarily demyelinating neuropathy, as has&#xD;
      been shown in nerve conduction studies and in histopathological investigations. The&#xD;
      conduction velocities of peripheral nerves are already slowed at the age of five years.&#xD;
      Longitudinal data show that these conduction velocities do not change during life, indicating&#xD;
      that the degree of demyelination is rather constant during life.&#xD;
&#xD;
      CMT1A is characterized clinically by distal muscle weakness and wasting, legs more than arms,&#xD;
      impaired distal sensation, and reduced or absent reflexes. Moreover, foot and hand&#xD;
      deformities are often encountered. In childhood, disease progression has been shown. In&#xD;
      adults, there are indications for disease progression, but properly conducted longitudinal&#xD;
      studies are awaited. Cross-sectional studies show that disease severity in adults is&#xD;
      variable: a group of CMT1A patients is asymptomatic (5-10%), whereas other patients are&#xD;
      wheelchair dependent (5-10%), still most have the classical CMT phenotype. Therapy is&#xD;
      symptomatic and aims at maintaining functional possibilities and learning compensation&#xD;
      mechanisms. There is no medication available that stabilizes or improves the clinical signs&#xD;
      and symptoms.&#xD;
&#xD;
      Ascorbic acid is needed in in vitro studies for proper myelination of axons (in cultures&#xD;
      containing serum). Recently, in a mouse model for CMT1A it has been shown that ascorbic acid&#xD;
      improves the CMT1A phenotype. Mice (2-4 months old) treated with ascorbic acid once a week&#xD;
      during three months showed an increase in the percentage of myelinating nerve fibers and&#xD;
      showed better results in locomotor tests.&#xD;
&#xD;
      In this phase 2 study we will study the efficacy and safety of ascorbic acid in young&#xD;
      patients with CMT1A. We will investigate whether ascorbic acid induces remyelination by&#xD;
      measuring the nerve conduction of a peripheral nerve during a one year study period. CMT1A&#xD;
      patients aged 12 years or older may cooperate sufficiently in nerve conduction studies. We&#xD;
      include young patients, as clinical signs and symptoms especially develop relatively early in&#xD;
      life. These signs and symptoms are due to axonal dysfunction, secondary to the demyelination.&#xD;
      This is why we will investigate additionally whether there is an effect of ascorbic acid&#xD;
      treatment on axonal function, strength and disabilities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in motor nerve conduction velocity of the median nerve after 1 year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in minimal F response latency of the median nerve after 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in compound muscle action potential amplitude and area after 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor unit number estimation of the abductor pollicis brevis muscle after 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in handgrip strength, strength of armflexors, foot dorsiflexors, knee extensors and hip flexors after 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall disability sum score after 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AMC Linear Disability Scale score after 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum ascorbic acid concentrations during 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of side effects during 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Charcot-Marie-Tooth Disease</condition>
  <condition>Hereditary Motor and Sensory Neuropathies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascorbic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 4 capsules b.i.d. during 1 year</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ascorbic acid</intervention_name>
    <description>Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DNA-proven CMT1A patients&#xD;
&#xD;
          -  Age 12-25 years&#xD;
&#xD;
          -  CMT 1A patients with symptomatology defined as muscle weakness in at least foot&#xD;
             dorsiflexion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Due to possible influence on severity of the neuropathy:&#xD;
&#xD;
          -  Known other disease that may cause a neuropathy, that may decrease mobility, or that&#xD;
             may lead to severe disability or death in a short time&#xD;
&#xD;
          -  Medication that may cause a neuropathy&#xD;
&#xD;
          -  Chronic alcohol abuse&#xD;
&#xD;
        Due to study medication (ascorbic acid):&#xD;
&#xD;
          -  Regular use of vitamin C&#xD;
&#xD;
          -  Clinical or echographic signs of nephrolithiasis&#xD;
&#xD;
          -  Reduced glomerular filtration rate&#xD;
&#xD;
          -  Iron overload&#xD;
&#xD;
          -  No regular dental control at the dentist&#xD;
&#xD;
          -  Pregnancy or active pregnancy wish for women&#xD;
&#xD;
        Due to study design and primary outcome:&#xD;
&#xD;
          -  Not signing the informed consent&#xD;
&#xD;
          -  Psychiatric co-morbidity which may influence compliance&#xD;
&#xD;
          -  Not being comfortable during nerve conduction studies of the median nerve&#xD;
&#xD;
          -  A too small CMAP amplitude of the abductor pollicis brevis muscle for a proper&#xD;
             determination of the nerve conduction velocity of the median nerve&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Verhamme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Academic Medical Center, University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Vermeulen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Academic Medical Center, University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Baas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Academic Medical Center, University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. de Haan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Academic Medical Center, University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. de Visser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Academic Medical Center, University of Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I. N van Schaik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Academic Medical Center, University of Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology Academic Medical Center University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <state>P.O.Box 22660</state>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Font√©s M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004 Apr;10(4):396-401. Epub 2004 Mar 21.</citation>
    <PMID>15034573</PMID>
  </reference>
  <reference>
    <citation>Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, Vermeulen M, de Visser M. Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. J Neurol. 2004 Dec;251(12):1491-7.</citation>
    <PMID>15645349</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>January 3, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <last_update_submitted>July 2, 2008</last_update_submitted>
  <last_update_submitted_qc>July 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>C. Verhamme, MD</name_title>
    <organization>Academic Medical Center, university of Amsterdam</organization>
  </responsible_party>
  <keyword>Charcot-Marie-Tooth Disease</keyword>
  <keyword>Hereditary Motor and Sensory Neuropathies</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Vitamin C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

